GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK (GSK) stock fell after reporting a 2% YoY revenue decline in Q2 2024, driven by an 18% YoY drop in vaccine sales. Read ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.

Sales GSK Plc’s leading vaccines sank in the third quarter after the British drugmaker was hit by limited access to the shots ...

For anyone who wants to understand GSK's profit beyond the statutory numbers, it's important to note that during the last ...

Shares of GSK PLC GSK dropped 1.59% to £13.92 Tuesday, on what proved to be an all-around poor trading session for the stock ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...